Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology
Vincenzo Quagliariello(Cancer Institute (WIA)), Nicola Maurea(Cancer Institute (WIA)), Rosa Rapuano Lembo(University of Milan), Carlo Maurea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Margherita Passariello(Federico II University Hospital), Domenico Gabrielli(Azienda Ospedaliera San Camillo-Forlanini), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Isabella Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Marino Scherillo, Laura Manna(Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise G. Caporale), Maria Laura Canale(Ospedale Versilia), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 16
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k